| Proproteins and methods of use thereof |
2022-12-19 |
2023-6-15 |
|
| Matrix metalloprotease-cleavable and serine protease-cleavable substrates and … |
2022-12-07 |
2023-7-06 |
|
| Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 … |
2022-10-26 |
2022-12-27 |
|
| Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use … |
2022-10-21 |
2023-1-10 |
|
| Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide … |
2022-10-17 |
2023-4-20 |
|
| Activatable polypeptide complex |
2022-10-14 |
2023-6-08 |
|
| Activatable polypeptide complex |
2022-10-14 |
2023-6-15 |
|
| Trimeric activatable cytokine constructs and related compositions and methods |
2022-10-12 |
2023-4-20 |
|
| Activatable cytokine constructs and related compositions and methods |
2022-10-11 |
2022-12-01 |
|
| Activatable cytokine constructs and combination methods |
2022-10-06 |
2023-6-22 |
|
| Activatable cytokine constructs and related compositions and methods |
2022-10-06 |
2023-4-13 |
|
| Compositions containing activatable antibodies |
2022-9-19 |
2022-11-01 |
|
| Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use … |
2022-9-15 |
2022-10-06 |
|
| Antibodies, activatable antibodies, bispecific antibodies, and bispecific … |
2022-9-07 |
2023-2-16 |
|
| Method for determining protease activity in a biological sample |
2022-8-30 |
2023-3-09 |
|
| AURISTATIN-RELATED COMPOUNDS, AURISTATIN CONJUGATED COMPOUNDS AND METHODS OF … |
2022-8-04 |
2022-10-31 |
|
| Matriptase and u-plasminogen activator polypeptide substrates and other … |
2022-7-14 |
2023-6-01 |
|
| Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use … |
2022-6-08 |
2022-8-17 |
|
| Anti-cd166 antibodies, activatable anti-cd166 antibodies, compositions … |
2022-5-04 |
2022-7-01 |
|
| MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS |
2022-3-16 |
2023-6-07 |
|
| Masked activatable cytokine constructs and related compositions and methods |
2022-3-16 |
2023-2-01 |
|
| Anti-cd40 antibodies and uses thereof |
2022-3-15 |
2022-10-13 |
|
| Matrix metalloproteinase cleavable polypeptides and uses thereof |
2022-3-13 |
2022-5-01 |
|
| Activatable anti-ctla-4 antibodies and uses thereof |
2022-3-09 |
2022-6-21 |
|
| Multispecific antibodies, multispecific activatable antibodies, and methods of … |
2022-2-25 |
2022-4-26 |
|
| Composition and method for detecting protease activity in biological system |
2021-12-23 |
2022-3-04 |
|
| Method of treating or delaying progression of an epidermal growth factor … |
2021-11-22 |
2022-9-15 |
|
| Anti-cd166 antibodies and uses thereof |
2021-11-09 |
2022-8-04 |
|
| Protease-resistant systems for polypeptide display and methods of making and … |
2021-11-08 |
2022-7-28 |
|
| Activatable anti-pdl1 antibodies, and methods of use thereof |
2021-9-10 |
2022-5-26 |
|
| ACTIVATABLE BINDING POLYPEPTIDES AND METHODS FOR IDENTIFICATION AND USES … |
2021-7-05 |
2023-4-04 |
2023-4-04 |
| Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable … |
2021-6-06 |
2021-7-29 |
|
| Activatable anti-cd166 antibodies and methods of use thereof |
2021-5-02 |
2021-6-30 |
|
| Epcam antibodies, activatable antibodies, and immunoconjugates, and uses … |
2021-4-20 |
2021-6-30 |
|
| Compositions and methods for conjugating activatable antibodies |
2021-4-09 |
2022-3-24 |
|
| Single-and multi-chain polypeptides that bind specifically to cd3 epsilon |
2021-1-06 |
2023-2-23 |
|
| Activatable antibodies having non-binding steric moieties and methods of using … |
2020-12-08 |
2021-10-07 |
|
| Activatable binding polypeptides and methods of identification and use thereof |
2020-12-04 |
2023-2-23 |
2023-2-23 |
| Modified antibody compositions, methods of making and using thereof |
2020-10-22 |
2021-9-16 |
|
| Therapeutic antibodies |
2020-10-12 |
2021-9-02 |
|
| Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use … |
2020-9-23 |
2021-4-01 |
|
| Activatable anti-cd166 antibodies and methods of use thereof |
2020-7-21 |
2021-4-08 |
|
| Matriptase and u-plasminogen activator substrates and other cleavable moieties … |
2020-7-14 |
2023-9-07 |
2023-9-07 |
| Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a … |
2020-6-12 |
2020-12-17 |
|
| Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a … |
2020-6-12 |
2022-4-20 |
|
| Activatable antibodies that bind epidermal growth factor receptor and methods … |
2020-6-04 |
2021-1-28 |
|
| Methods and compositions for determining the biodistribution of activatable … |
2020-5-17 |
2022-7-21 |
|
| Combination therapy of activatable immune checkpoint inhibitors and conjugated … |
2020-2-26 |
2021-11-19 |
|
| Activatable antibodies that bind interleukin-6 receptor and methods of use … |
2020-2-20 |
2020-10-29 |
|
| Antibodies, activatable antibodies, bispecific antibodies, and bispecific … |
2019-5-02 |
2020-4-16 |
|
| Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged … |
2019-4-05 |
2019-12-05 |
|
| Systems and methods for quantitative pharmacological modeling of activatable … |
2019-3-20 |
2020-11-27 |
|
| Activatable cd147 antibodies and methods of making and use thereof |
2019-3-08 |
2019-9-12 |
|
| Positron emission tomography imaging of activatable binding polypeptides and … |
2019-2-21 |
2020-12-31 |
|
| Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use … |
2019-1-18 |
2019-10-10 |
|
| ANTIBODIES, ACTIVABLE ANTIBODIES, BI-SPECIFIC ANTIBODIES, AND BI-SPECIFIC … |
2018-10-12 |
2020-5-06 |
|
| Anti-cd71 activatable antibody drug conjugates and methods of use thereof |
2018-10-12 |
2019-4-18 |
|
| Methods of qualitatively and/or quantitatively analyzing properties of … |
2018-7-20 |
2020-1-16 |
|
| Activatable anti-pdl1 antibodies, and methods of use thereof |
2018-5-31 |
2018-12-06 |
|
| CD147 antibodies, activatable CD147 antibodies, and methods of making and using … |
2018-3-09 |
2020-1-07 |
|
| Antibodies that bind activatable antibodies and methods of use thereof |
2017-7-26 |
2020-2-25 |
2020-2-25 |
| Antibodies specific for urokinase-type plasminogen activator and methods of use … |
2017-5-30 |
2019-3-26 |
2019-3-26 |
| Anti-cd166 antibodies, and activatable anti-cd166 antibodies, and methods of … |
2016-5-04 |
2022-10-13 |
|
| ANTIBODIES AGAINST THE TRANSFERRINE RECEIVER (ANTI-CD71), ANTI-CD71 ACTIVABLES … |
2016-5-04 |
2017-9-27 |
|
| Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use … |
2016-3-14 |
2022-3-01 |
|
| Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use … |
2016-3-14 |
2022-3-04 |
|
| ISOLATED POLYPEPTIDE COMPRISING A CLEAVABLE REGION (CM) WHICH IS A MATRIX … |
2014-9-25 |
2023-5-30 |
|
| Polipeptídeo isolado que compreende uma região clivável (cm) que é um substrato … |
2014-9-25 |
2023-5-30 |
|